Reprogramming Immunity: Tr1X Prepares to Showcase Breakthrough Cell Therapy Data

SAN DIEGO – April 27, 2026 – In the high-stakes world of biotechnology, the pursuit of a true “immune reset” has long been a coveted goal. San Diego-based Tr1X, Inc. is poised to take a significant step in that direction, announcing it will present promising new data for its engineered Type 1 regulatory T (Tr1) cell therapies at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May.

The clinical-stage company will deliver two key oral presentations highlighting the progress of its lead candidate, TRX103 for transplant complications, and its next-generation program, TRX319 for progressive multiple sclerosis. The data represents a critical milestone for Tr1X’s platform, which aims to move beyond chronic immunosuppression and instead offer durable, potentially curative treatments by re-establishing immune balance.

“We are excited to present data across our allogeneic engineered Tr1 platform that highlight the potential of these therapies to reprogram the immune system in a precise and durable way,” said Dr. Maria Grazia Roncarolo, Co-Founder, President and Head of R&D at Tr1X, in a recent statement. Dr. Roncarolo is a world-renowned immunologist credited with the discovery of Tr1 cells, and her work forms the scientific bedrock of the company. “These results reinforce our belief that Tr1 regulatory cell therapies represent a differentiated approach to treating immune-mediated diseases.”

A Tolerogenic Shield Against Transplant Rejection

One of the most significant hurdles in medicine is Graft-versus-Host Disease (GvHD), a life-threatening complication where donor immune cells attack the recipient’s body following a hematopoietic stem cell transplant. Tr1X’s lead program, TRX103, is being developed specifically to prevent this devastating condition.

At the ASGCT meeting, the company will present first-in-human Phase 1 data on TRX103 in patients undergoing HLA-mismatched transplants. The findings are highly encouraging. According to the company, the therapy was well-tolerated with no dose-limiting toxicities observed. More importantly, it demonstrated proof of mechanism: TRX103 showed dose-dependent persistence and expansion in patients while actively creating a “tolerogenic environment.”

This environment is characterized by an increase in IL-10, a potent anti-inflammatory cytokine that is a hallmark of Tr1 cell function, and a corresponding reduction in pro-inflammatory cytokines that fuel GvHD. This ability to actively modulate and calm the immune system, rather than simply suppressing it, distinguishes TRX103 from conventional treatments like steroids or broad immunosuppressants, which can carry significant side effects and are not always effective. The therapy’s ability to induce this protective state offers a glimpse into a future where transplants can be made safer and accessible to more patients.

A Dual-Action Strategy for Progressive Multiple Sclerosis

Beyond transplantation, Tr1X is leveraging its platform to tackle one of neurology’s most formidable challenges: progressive multiple sclerosis (MS). While many treatments exist for relapsing-remitting MS, options for the progressive forms of the disease, which are characterized by steady neurological decline, remain limited.

The company’s second presentation will unveil preclinical data for TRX319, a novel CAR-Tr1 therapy engineered for this purpose. The therapy employs a sophisticated dual-action strategy. First, it uses a Chimeric Antigen Receptor (CAR) targeting CD19 to deplete B cells, a key driver of inflammation and damage in MS. This approach aligns with emerging CAR-T therapies that have shown early promise in autoimmune disease.

However, TRX319 goes a step further by combining B cell depletion with the inherent immunoregulatory power of Tr1 cells. Preclinical data demonstrate that the therapy not only eliminates harmful B cells but also suppresses autoreactive T cells and reduces inflammatory activity in microglia, the resident immune cells of the central nervous system. This multi-pronged attack on the core drivers of MS pathology supports its advancement into clinical trials and positions it as a highly differentiated candidate in a competitive field.

The 'Off-the-Shelf' Revolution in Cell Therapy

A central pillar of Tr1X’s strategy is its focus on developing allogeneic, or “off-the-shelf,” therapies. Unlike autologous treatments, which are custom-made for each patient using their own cells—a costly and time-consuming process—allogeneic therapies are manufactured in large batches from the cells of healthy donors and cryopreserved for immediate use.

This approach promises to democratize cell therapy, making it more scalable, affordable, and accessible. Patients could receive treatment on demand, without the weeks-long manufacturing delays and logistical hurdles associated with personalized therapies. However, the allogeneic model has its own challenges, primarily the risk of the patient’s body rejecting the donor cells or the donor cells causing GvHD.

Tr1X believes its Tr1 cell platform provides an elegant solution. Tr1 cells are naturally immunoregulatory and are known for their ability to induce tolerance. By engineering these specific cells, the company aims to create a product that can not only perform its therapeutic function but also protect itself from immune rejection, potentially reducing or eliminating the need for harsh conditioning chemotherapy. This intrinsic property could be the key to unlocking the full commercial and clinical potential of off-the-shelf cell therapies.

Building a Future of Curative Therapies

Backed by $125 million in financing from prominent investors like The Column Group, Lux Capital, and Alexandria Ventures, Tr1X has the financial runway to advance its ambitious pipeline into 2027. The company’s strategy is not just to treat symptoms but to address the root cause of immune dysfunction.

By leveraging a versatile platform that can be adapted with different engineering strategies—from the foundational TRX103 to the advanced CAR-Tr1 design of TRX319—Tr1X is demonstrating a path toward creating targeted, durable therapies for a range of intractable autoimmune and inflammatory conditions. The upcoming presentations at ASGCT will provide the scientific community and the broader public with a crucial look at the data supporting this vision, potentially heralding a new era where reprogramming the immune system becomes a clinical reality.